ClinicalTrials.gg
RecruitingNCT07023588Updated Aug 8, 2025

Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

A Phase 2 interventional study of Venetoclax in Acute Myeloid Leukemia (AML), sponsored by Yehui Tan. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-08.

Sponsored by Yehui Tan · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 203 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 145 under way, 22 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Planned enrollment
91st of 203
70 · median 58
Started
2025
with 21 others
Phase 2
89 of 203
57 open now
Primary completion
2029-05
later than 122 of 144 live
Registered
166th of 203
by date

Among the 203 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 91st largest by planned enrollment, is one of 22 that started in 2025, is one of 89 in phase 2, reaches primary completion later than 122 of the 144 other live ones, and was the 166th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 203 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease

Read the detailed description

This study is a randomized controlled, prospective clinical trial, with the leading unit being the First Hospital of Jilin University. It aims to screen patients with a suboptimal response to chemotherapy based on early peripheral blood minimal residual disease (MRD) levels, and explore the efficacy and safety of adding venetoclax. A total of 70 subjects are expected to be enrolled, with 35 subjects each in the experimental group and the control group. The study will collect data on subjects' demographics, other baseline characteristics, medication usage, prognosis, etc. Statistical analysis will be performed on the collected data to compare efficacy indicators.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Newly diagnosed AML patients confirmed by bone marrow morphology and immunophenotyping.
  2. Complete MICM (Morphology, Immunophenotyping, Cytogenetics, Molecular genetics) work-up.
  3. Age ≥ 18 years.
  4. (ECOG) performance status of 0-2.
  5. Day 6 Peripheral Blood Blast Percentage (D6PBBP) ≥ 1%.
  6. Renal function with ≥ 50 mL/min (calculated using the Cockcroft-Gault formula or measured by 24-hour urine collection).
  7. Liver function with (AST) ≤ 2.5 × *; Alanine Aminotransferase (ALT) ≤ 2.5 × ULN*; Total ≤ 1.5 × ULN* (*Unless considered due to leukemia infiltration).
  8. Patients deemed suitable to receive DA/IA therapy by the investigator.
  9. Signed form. -

Exclusion criteria

Exclusion Criteria:

  1. Acute promyelocytic leukemia (APL).
  2. Mixed phenotype acute leukemia (MPAL).
  3. AML patients with known central nervous system (CNS) involvement.
  4. Presence of extramedullary disease (EMD).
  5. Significant hepatic or renal dysfunction exceeding the inclusion criteria limits.
  6. Severe cardiac disease, including congestive heart failure, myocardial infarction, or cardiac dysfunction.
  7. Concurrent active of other organ systems (patients with a history of cured malignancy may be eligible).
  8. Active tuberculosis or -positive patients.
  9. Concurrent other hematological disorders.
  10. Pregnant or lactating women.
  11. Inability to comprehend or comply with the study protocol.
  12. to any component of the drugs involved in the protocol.
  13. Inability to take oral medication or patients with malabsorption syndrome.
  14. Uncontrolled systemic infection.
  15. Prior venetoclax treatment and/or current participation in any other study involving agents.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    venetoclax,8-14d

    Drug: Venetoclax

  • No intervention
    Control group

Interventions

  • Patients identified with a suboptimal response to chemotherapy based on minimal residual disease (MRD) levels in peripheral blood on Day 6 will initiate venetoclax therapy added on Day 8, administered for 7 days.

06

What researchers measure

Primary outcomes

  1. Modified Composite Complete Response Rate(mCRc)

    Complete Response(CR) + Complete Response with Incomplete Hematologic Recovery(CRi)+Morphologic Leukemia Free State(MLFS)

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Overall Survival (OS)

    Defined as the time from enrollment in this study to death from any cause. If the exact date of death is unknown, the time of death is defined as the last contact date. If the patient is still alive, the last observed time will be used, and the patient's OS will be considered for analysis.

    Time frame: From date of index treatment to death, disease progression, or end of study, whichever came first, assessed up to 48 months.

  2. MRD Negative Conversion Rate

    Defined as the proportion of patients who convert to MRD negative among all evaluable patients for efficacy.

    Time frame: Through study completion, an average of 1 year

  3. Relapse-Free Survival(RFS)

    Defined as the time from enrollment in this study to the occurrence of relapse. For patients without relapse, the time is calculated until death from any cause or the time of the last follow-up

    Time frame: From date of index treatment to death, disease progression, or end of study, whichever came first, assessed up to 48 months.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2029, 47 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 47 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2025
First posted
Jun 17, 2025
StartActual
Jun 1, 2025
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Aug 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07023588
Lead sponsor
Yehui Tan
Responsible party
Yehui Tan (Professor, The First Hospital of Jilin University) — Sponsor-investigator
First posted
Jun 17, 2025
Start date
Jun 1, 2025
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Aug 8, 2025

Study contacts

Yehui Tan
Contact
yhtan@jlu.edu.cn
8615948027438
Yuying Li
Contact
lyying1001@jlu.edu.cn
8613944135650

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion